These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38907548)

  • 1. The efficacy of ixekizumab treatment in Chinese psoriasis patients: a short-term retrospective study.
    Yao X; Yuan J; Zhang Y; Li Y
    Eur J Dermatol; 2024 Apr; 34(2):176-181. PubMed ID: 38907548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
    Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
    Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial.
    Paller AS; Seyger MMB; Magariños GA; Pinter A; Cather JC; Rodriguez-Capriles C; Zhu D; Somani N; Garrelts A; Papp KA;
    JAMA Dermatol; 2022 May; 158(5):533-541. PubMed ID: 35416908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).
    Paller AS; Seyger MMB; Alejandro Magariños G; Bagel J; Pinter A; Cather J; Keller S; Rodriguez Capriles C; Gontijo Lima R; Gallo G; Little CA; Edson-Heredia E; Li L; Xu W; Papp K;
    Br J Dermatol; 2020 Aug; 183(2):231-241. PubMed ID: 32316070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
    Gordon KB; Blauvelt A; Papp KA; Langley RG; Luger T; Ohtsuki M; Reich K; Amato D; Ball SG; Braun DK; Cameron GS; Erickson J; Konrad RJ; Muram TM; Nickoloff BJ; Osuntokun OO; Secrest RJ; Zhao F; Mallbris L; Leonardi CL; ; ;
    N Engl J Med; 2016 Jul; 375(4):345-56. PubMed ID: 27299809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
    Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
    J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exposure-Response Modeling to Characterize the Relationship Between Ixekizumab Serum Drug Concentrations and Efficacy Responses at Week 12 in Patients With Moderate to Severe Plaque Psoriasis.
    Chigutsa E; Velez de Mendizabal N; Chua L; Heathman M; Friedrich S; Jackson K; Reich K
    J Clin Pharmacol; 2018 Nov; 58(11):1489-1500. PubMed ID: 29878382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study.
    Paul C; Griffiths CEM; van de Kerkhof PCM; Puig L; Dutronc Y; Henneges C; Dossenbach M; Hollister K; Reich K
    J Am Acad Dermatol; 2019 Jan; 80(1):70-79.e3. PubMed ID: 29969700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: Subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1).
    Imafuku S; Torisu-Itakura H; Nishikawa A; Zhao F; Cameron GS;
    J Dermatol; 2017 Nov; 44(11):1285-1290. PubMed ID: 28635026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).
    Blauvelt A; Papp KA; Griffiths CEM; Puig L; Weisman J; Dutronc Y; Kerr LF; Ilo D; Mallbris L; Augustin M
    Am J Clin Dermatol; 2017 Apr; 18(2):273-280. PubMed ID: 28074446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An indirect comparison of long-term efficacy of every-2-week dosing vs. recommended dosing of ixekizumab in patients who had static Physician's Global Assessment > 1 at week 12.
    Papp K; Maari C; Cauthen A; Gooderham M; Spelman L; Yamanaka K; Polzer P; Zhang L; Osuntokun O; Augustin M
    Br J Dermatol; 2020 Jul; 183(1):52-59. PubMed ID: 31545506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
    Griffiths CE; Reich K; Lebwohl M; van de Kerkhof P; Paul C; Menter A; Cameron GS; Erickson J; Zhang L; Secrest RJ; Ball S; Braun DK; Osuntokun OO; Heffernan MP; Nickoloff BJ; Papp K;
    Lancet; 2015 Aug; 386(9993):541-51. PubMed ID: 26072109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ixekizumab improves disease severity, clinical symptoms and quality of life in patients with genital psoriasis: A 24-week real-life experience.
    Calianno G; Esposito M; Fidanza R; Palmieri M; Fargnoli MC
    Dermatol Ther; 2021 Jul; 34(4):e14993. PubMed ID: 34029442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3).
    Papp KA; Leonardi CL; Blauvelt A; Reich K; Korman NJ; Ohtsuki M; Paul C; Ball S; Cameron GS; Erickson J; Zhang L; Mallbris L; Griffiths CEM
    Br J Dermatol; 2018 Mar; 178(3):674-681. PubMed ID: 28991370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3).
    Reich K; Leonardi C; Lebwohl M; Kerdel F; Okubo Y; Romiti R; Goldblum O; Dennehy EB; Kerr L; Sofen H
    J Dermatolog Treat; 2017 Jun; 28(4):282-287. PubMed ID: 27759463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: A Prospective, Multicenter, Observational Study.
    Ying L; Suyun J; Yanhua L; Yunsheng L; Li D; Lin D; Chengzhi L; Bingjiang L; Furen Z; Wendi S; Jinnan L; Yu D; Guanshen D; Shi Y
    Adv Ther; 2023 Dec; 40(12):5464-5474. PubMed ID: 37824031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab.
    Blauvelt A; Muram TM; See K; Mallinckrodt CH; Crowley JJ; van de Kerkhof P
    J Dermatolog Treat; 2018 May; 29(3):220-229. PubMed ID: 28792259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nail Psoriasis Does Not Affect Skin Response to Ixekizumab in Patients With Moderate-To-Severe Psoriasis.
    Rich P; Goldblum O; Disch D; Lin CY; Merola JF; Elewski B
    J Drugs Dermatol; 2020 Aug; 19(8):741-746. PubMed ID: 32845588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis.
    Zachariae C; Gordon K; Kimball AB; Lebwohl M; Blauvelt A; Leonardi C; Braun D; McKean-Matthews M; Burge R; Cameron G
    J Am Acad Dermatol; 2018 Aug; 79(2):294-301.e6. PubMed ID: 29653208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.